Clinical Trial

Efficacy of CL25216 on Vasomotor Symptoms in Women During Perimenopause

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 5, 2025 (before its estimated June 12, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is to evaluate the effects of CL25216 on vasomotor symptoms in women during Perimenopause. Enrolled subjects will receive either CL25216 - 250 mg/day or placebo.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-02; most recent amendment 2025-11-28.
Status change: Not Yet Recruiting → Recruiting 2025-11-28
Trial Details
NCT Number NCT07112651
Lead Sponsor ApexCPG LLC
Conditions Vasomotor Symptoms
Enrollment 80 participants
Start Date 2025-11-24
Primary Completion 2026-06-12 (estimated)
Study Completion 2026-06-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-05